Bruker Co. (NASDAQ:BRKR) Given Average Recommendation of "Moderate Buy" by Analysts

Bruker Co. (NASDAQ:BRKR - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven analysts that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $70.50.

Several research analysts have recently commented on the company. UBS Group assumed coverage on Bruker in a report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price objective on the stock. Barclays decreased their price objective on Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus reduced their price target on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Bank of America boosted their price target on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a report on Friday, December 13th. Finally, Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Gordian Capital Singapore Pte Ltd purchased a new stake in Bruker during the 4th quarter valued at $234,000. EDENTREE ASSET MANAGEMENT Ltd boosted its stake in Bruker by 11.2% during the 4th quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company's stock valued at $9,262,000 after purchasing an additional 15,900 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Bruker by 17.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company's stock valued at $20,926,000 after purchasing an additional 52,214 shares during the last quarter. Voloridge Investment Management LLC boosted its stake in Bruker by 179.6% during the 4th quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company's stock valued at $1,108,000 after purchasing an additional 12,145 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in Bruker by 406.1% during the 4th quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company's stock valued at $8,248,000 after purchasing an additional 112,900 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Trading Down 1.3 %

NASDAQ BRKR opened at $44.96 on Thursday. The stock's 50-day simple moving average is $54.21 and its two-hundred day simple moving average is $58.66. Bruker has a twelve month low of $44.82 and a twelve month high of $94.86. The company has a quick ratio of 0.77, a current ratio of 1.60 and a debt-to-equity ratio of 1.15. The company has a market capitalization of $6.82 billion, a price-to-earnings ratio of 59.16, a PEG ratio of 2.16 and a beta of 1.18.

Remove Ads

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Research analysts forecast that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.44%. Bruker's payout ratio is currently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.